Nagahisa Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nagahisa Okamoto has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Teruhiko Higuchi
4 shared publicationsKota Sakamoto
3 shared publicationsYuko Nagafusa
2 shared publications- Hiroaki Hori
National Center of Neurology and Psychiatry
1 shared publication Hirofumi Uchiyama
1 shared publication- Hiroshi Kunugi
Department of Psychiatry Teikyo University School of Medicine Tokyo Japan
1 shared publication
Latest Publications
- 1 September 2011
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 26, e110-e111
Genetic variations of fyn-tyrosine kinase in Psychiatric disorders
- 1 September 2011
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 26, e110-e111
Genetic variations of fyn-tyrosine kinase in Psychiatric disorders
- 1 September 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (3) , 223-227
Rapid Antidepressant Effect of Ketamine Anesthesia During Electroconvulsive Therapy of Treatment-Resistant Depression
Reports of the superiority of the antidepressant effect of ketamine during the conduct of electroconvulsive therapy (ECT) have been limited. We conducted an open-label trial of ketamine to determine whether ketamine as the anesthetic during ECT would provide a greater antidepressant effect than the antidepressant effect obtained with propofol. Between April 2006 and April 2007, 31 inpatients with treatment-resistant depression gave written consent for ECT and to participate in this study. An anesthesiologist who was unaware of the mental symptoms of the subjects assigned them to receive propofol or ketamine anesthetic according to the preferences of the patients, and the patients underwent 8 ECT sessions for 4 weeks. The Hamilton Depression Rating Scale (HDRS) was valuated before ECT and after the completion of the second, fourth, sixth, and eighth ECT sessions. The HDRS scores improved earlier in the ketamine group, with decreases in HDRS scores that were significantly greater in the ketamine group. The results suggested that it is possible to improve symptoms of depression earlier by using ketamine anesthesia.
- 1 September 2010
- Published by Wolters Kluwer Health in The Journal of ECT
- Vol. 26 (3) , 223-227
Rapid Antidepressant Effect of Ketamine Anesthesia During Electroconvulsive Therapy of Treatment-Resistant Depression
Reports of the superiority of the antidepressant effect of ketamine during the conduct of electroconvulsive therapy (ECT) have been limited. We conducted an open-label trial of ketamine to determine whether ketamine as the anesthetic during ECT would provide a greater antidepressant effect than the antidepressant effect obtained with propofol. Between April 2006 and April 2007, 31 inpatients with treatment-resistant depression gave written consent for ECT and to participate in this study. An anesthesiologist who was unaware of the mental symptoms of the subjects assigned them to receive propofol or ketamine anesthetic according to the preferences of the patients, and the patients underwent 8 ECT sessions for 4 weeks. The Hamilton Depression Rating Scale (HDRS) was valuated before ECT and after the completion of the second, fourth, sixth, and eighth ECT sessions. The HDRS scores improved earlier in the ketamine group, with decreases in HDRS scores that were significantly greater in the ketamine group. The results suggested that it is possible to improve symptoms of depression earlier by using ketamine anesthesia.
- Open Access
- 1 January 2010
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 2 (2) , 52-56
Major Depressive Disorder Complicated with Spinocerebellar Ataxia: Report of 2 Cases
Background: It is known that patients with spinocerebellar ataxia (SCA) tend to exhibit depressive symptoms. But the pathology of depressive symptoms complicated with SCA, including the reaction to the stress resulting from decreased motor function and central dysfunction due to neurodegeneration, is controversial and remains to be elucidated. To our knowledge, there have been hardly any reports on treatment methods of major depressive disorder (MDD) complicated with SCA. Case Reports: We report 2 cases in which selective serotonin reuptake inhibitors (SSRIs) were effective against MDD complicated with SCA. Interestingly, one of the patients developed the symptoms of spinocerebellar degeneration (SCD) during the course of the MDD, and the other patient developed the symptoms of MDD during the course of SCA, but complete remission of the MDD occurred in both cases. In our cases, the depressive symptoms may have been caused mainly by an abnormality of reversible neural transmission including serotonin transmission due to central dysfunction, and there is the unlikely possibility that the depressive symptoms are reactive to the stress due to decreased motor function, because the depressive symptoms decreased with SSRIs. Conclusion: Although cerebellar degeneration is irreversible in SCA patients, our cases suggest that MDD complicated with SCA may be reversible and treatable using antidepressants such as SSRIs with few adverse events. Therefore, it is important for neurologists to detect MDD complicated with SCA early and consult a psychiatrist in order to improve quality of life of SCA patients.
- 1 January 2010
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 2 (2) , 52-56
Open AccessMajor Depressive Disorder Complicated with Spinocerebellar Ataxia: Report of 2 Cases
Background: It is known that patients with spinocerebellar ataxia (SCA) tend to exhibit depressive symptoms. But the pathology of depressive symptoms complicated with SCA, including the reaction to the stress resulting from decreased motor function and central dysfunction due to neurodegeneration, is controversial and remains to be elucidated. To our knowledge, there have been hardly any reports on treatment methods of major depressive disorder (MDD) complicated with SCA. Case Reports: We report 2 cases in which selective serotonin reuptake inhibitors (SSRIs) were effective against MDD complicated with SCA. Interestingly, one of the patients developed the symptoms of spinocerebellar degeneration (SCD) during the course of the MDD, and the other patient developed the symptoms of MDD during the course of SCA, but complete remission of the MDD occurred in both cases. In our cases, the depressive symptoms may have been caused mainly by an abnormality of reversible neural transmission including serotonin transmission due to central dysfunction, and there is the unlikely possibility that the depressive symptoms are reactive to the stress due to decreased motor function, because the depressive symptoms decreased with SSRIs. Conclusion: Although cerebellar degeneration is irreversible in SCA patients, our cases suggest that MDD complicated with SCA may be reversible and treatable using antidepressants such as SSRIs with few adverse events. Therefore, it is important for neurologists to detect MDD complicated with SCA early and consult a psychiatrist in order to improve quality of life of SCA patients.
- 1 January 2010
- Published by Elsevier in The Lancet
- Vol. 375 (9711) , 346
Major depression: what caused the crisis?
- 1 January 2010
- Published by Elsevier in The Lancet
- Vol. 375 (9711) , 346
Major depression: what caused the crisis?